Boston, MA -- (SBWIRE) -- 05/19/2014 -- Amyotrophic lateral sclerosis (ALS), often referred to as "Lou Gehrig's Disease," is a rare, but fatal, progressive neurodegenerative disease that affects the nerve cells in the brain and the spinal cord. ALS severely impacts physical functioning and initially presents with muscle twitching, weakness in an arm or leg, or with slurring of speech. Eventually, people with ALS lose their ability to control the muscles needed to move, speak, eat, and breathe, which ultimately leads to death. The progressively degenerative course of the condition is a great burden for both patients and caregivers, as well as for society.
GlobalData epidemiologists forecast that the diagnosed prevalent cases of ALS in the 7MM will grow by 13.5% over the next decade, from 32,698 diagnosed prevalent cases in 2013 to 37,122 diagnosed prevalent cases in 2023. Throughout the forecast period, the US will have the highest numbers of diagnosed prevalent cases of ALS, followed by Japan.
View Full Report Details and Table of Contents
To develop the epidemiological forecast for the diagnosed prevalent cases of ALS in the 7MM, GlobalData epidemiologists obtained the diagnosed prevalence data for ALS from peer-reviewed journals and population-based studies in the respective markets and used a consistent methodology to ensure comparability of the results. A major strength of GlobalData's epidemiological analysis is the use of country-specific studies that provided the diagnosed prevalence of ALS using uniform diagnostic criteria based on the El Escorial criteria or the International Classification of Diseases, Ninth Revision (ICD-9), criteria (ICD-9 code for ALS = 335.2), to allow for a meaningful comparison of the diagnosed prevalent cases of ALS in these markets. Furthermore, the diagnosed prevalent cases of ALS in each of the 7MM were further segmented by age and sex in order to provide a more detailed analysis of the patient population.
- The Amyotrophic lateral sclerosis (ALS) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for ALS in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of ALS segmented by age (=40 years) and sex in these markets.
- The ALS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to Get This Report
- Develop business strategies by understanding the trends shaping and driving the global ALS market.
- Quantify patient populations in the global ALS market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for ALS therapeutics in each of the markets covered.
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2014
- EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2023
- EpiCast Report: Allergic Rhinitis - Epidemiology Forecast to 2023
- EpiCast Report: Migraine - Epidemiology Forecast to 2023
- Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013
- EpiCast Report: Overweight and Obesity - Epidemiology Forecast to 2022
- EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2022
- EpiCast Report: Trigeminal Neuralgia - Epidemiology Forecast to 2022
- EpiCast Report: Gram-Negative Bacterial Urinary Tract Infection - Epidemiology Forecast to 2022
- EpiCast Report: Breast Cancer - Epidemiology Forecast to 2022